Clinical trials: Autologous Blood Transfusion
Beta-Thalassemia
An Open-label Study of a Gene Therapy Product (Vebeglogene Autotemcel) in Transfusion Dependent Beta-Thalassemia
This is an interventional study to evaluate the safety and efficacy of autologous Hematopoietic Stem and Progenitor Cells (HSPCs) transduced with lentiviral vector encoding functional hemoglobin subunit beta (HBB) gene in…
- Trial name
- NCT06308159
- Testing
- Vebeglogene autotemcel
- Where
- 2 sites in China
- Volunteers
- 6 people
- Sponsor
- Lantu Biopharma
Type 1 Diabetes
Cord Blood Plus Vitamin D and Omega 3s in T1D
In this pilot study the investigators are trying to see if a single intravenous infusion of autologous (self) cord blood cells followed by 1 year of daily vitamin D and omega 3 fatty acid supplementation can preserve beta cell…
- Trial name
- NCT00873925
- Testing
- Autologous UCB, Omega 3 FA, Vitamin D
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Florida
Beta-Thalassemia, Thalassemia
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
This is a single-dose, open-label study in participants with transfusion-dependent β-thalassemia (TDT) or severe sickle cell disease (SCD).
- Conditions
- Beta-Thalassemia, Thalassemia, Hematologic Diseases, Genetic Diseases, Inborn
- Trial name
- NCT05477563
- Testing
- CTX001
- Where
- 6 sites in United States, Germany and 2 more
- Volunteers
- 26 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Sickle Cell Disease, Transfusion-dependent Beta-Thalassemia
A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301
The purpose of this study is to evaluate the long-term safety and efficacy of EDIT-301 in participants with severe sickle cell disease (SCD) or transfusion-dependent β-thalassemia (TDT) who have received EDIT-301.
- Conditions
- Sickle Cell Disease, Transfusion-dependent Beta-Thalassemia, Hemoglobinopathies
- Trial name
- NCT06363760
- Testing
- Safety and efficacy assessments
- Where
- 18 sites in United States, Canada
- Volunteers
- 54 people
- Sponsor
- Editas Medicine, Inc.
Beta-Thalassemia
Gene Therapy for Transfusion Dependent Beta-thalassemia
This is a phase I/II study evaluating safety and efficacy of autologous hematopoietic stem cells genetically modified with GLOBE lentiviral vector encoding for the human beta-globin gene for the treatment of patients affected by…
- Trial name
- TIGET-BTHAL (NCT02453477)
- Testing
- Autologous hematopoietic stem cells genetically modified with GLOBE lentiviral vector encoding for the human beta-globin gene
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- IRCCS San Raffaele
Beta-Thalassemia, Thalassemia
A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia
This is a single-arm, open-label, multi-site, single-dose Phase 1/2/3 study in participans with transfusion-dependent β-thalassemia (TDT).
- Conditions
- Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn, Hematologic Diseases
- Trial name
- NCT03655678
- Testing
- CTX001
- Where
- 14 sites in United States, Canada and 3 more
- Volunteers
- 59 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Anemia of Prematurity
Autologous Cord Blood Transfusion in Preterm Infants
The purpose of this study is to investigate the efficacy and safety of autologous cord blood transfusions in very-low-birth-weight premature infants, and to evaluate the developmental outcomes of the infants who received…
- Trial name
- NCT02101086
- Testing
- Blood transfusion
- Where
- Turkey (Türkiye)
- Volunteers
- 39 people
- Sponsor
- Ankara University
Beta-Thalassemia
A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia
This is a single-arm, multi-site, single-dose, Phase 3 study in approximately 18 participants less than or equal to (<=) 50 years of age with transfusion-dependent β-thalassemia (TDT), who have a β0/β0, β0/IVS-I-110, or…
- Trial name
- NCT03207009
- Testing
- LentiGlobin BB305 Drug Product
- Where
- 9 sites in United States, France and 4 more
- Volunteers
- 19 people
- Sponsor
- Genetix Biotherapeutics Inc.
Safety Issues, Effect of Drugs
Safety and Efficacy of Autologous Umbilical Cord Blood Mononuclear Cells Transfusion in Neonates
To study the safety and efficacy of Autologous Umbilical Cord Blood Mononuclear Cells transfusion on clinical outcome in preterm infants
- Conditions
- Safety Issues, Effect of Drugs, Neonatal Death
- Trial name
- NCT03053076
- Testing
- Autologous Umbilical Cord Blood Mononuclear Cells Therapy, 0.9% Sodium Chloride
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Guangdong Women and Children Hospital
Transfusion-dependent α-Thalassemia
A Study Evaluating the Safety and Efficacy of the GMCN-508A Drug Product in Transfusion-dependent α-Thalassemia Participants
This is a non-randomized, open label, single-site, single-dose, phase 1 study in up to 5 participants (between 5 and 35 years of age, inclusive) with Transfusion-dependent α-thalassemia.
- Trial name
- NCT05757245
- Testing
- GMCN-508A Drug Product
- Where
- China
- Volunteers
- 5 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Coxarthrosis
Effects of the Sangvia Blood Collection System on Postoperative Infections in Orthopedic Patients
The purpose of this study is to compare the infection rate in patients receiving/not receiving their own blood, collected during surgery, during and after orthopedic surgery.
- Trial name
- NCT01725724
- Testing
- Autologous blood transfusion, Allogeneic blood transfusion
- Where
- 4 sites in Norway
- Volunteers
- 162 people
- Sponsor
- Haukeland University Hospital
Platelet Transfusion Refractoriness
Efficacy and Safety of Autologous Cryopreserved Platelets in Patients With PTR
The purpose of this study is to improve the platelet level of PTR patients; Prevent and improve bleeding; Help patients to successfully through the bone marrow suppression period after chemotherapy; Reduce the overall rate of PTR…
- Trial name
- NCT05761457
- Testing
- Cryopreserved autologous platelet transfusion
- Where
- China
- Volunteers
- 25 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Beta-Thalassemia Major, Sickle Cell Disease
A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in β-Thalassemia Major (Also Referred to as Transfusion-dependent β-Thalassemia [TDT]) and Sickle Cell Disease
This is a Phase 1/2, open label, safety, and efficacy study of the administration of LentiGlobin BB305 Drug Product to participants with either transfusion dependent beta-thalassemia (TDT) or sickle cell disease (SCD).
- Trial name
- NCT02151526
- Testing
- LentiGlobin BB305 Drug Product
- Where
- France
- Volunteers
- 7 people
- Sponsor
- Genetix Biotherapeutics Inc.
Arthroplasty Complications, Total Knee Arthroplasty
Is Self-transfusion Safe After Total Knee Arthroplasty in Terms of Nephrotoxicity of Gentamicin From Bone Cement?
Considering that the high local concentration of antibiotic from bone cement is delivered intravenously through the self-transfusion process, systematic toxicity has never been evaluated.
- Trial name
- NCT04505748
- Testing
- Self-transfusion device
- Where
- Greece
- Volunteers
- 40 people
- Sponsor
- University Hospital, Alexandroupolis
Heart Transplantation
Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Prevent Rejection in Heart Transplant Children
The investigators developed a protocol to isolate Treg cells from thymic tissue (thyTreg) discarded in pediatric cardiac surgeries.
- Trial name
- THYTECH (NCT04924491)
- Testing
- Autologous thyTreg
- Where
- Spain
- Volunteers
- 11 people
- Sponsor
- Rafael Correa-Rocha
Anemia, Blood Transfusions, Autologous
A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Facilitating the Presurgical Collection of Blood to be Used for Self-donation During Surgery on the Spine, Hip, or Knee.
The purpose of this study is to evaluate the safety and effectiveness of epoetin alfa at doses of 150, 300, or 600 units per kilogram of body weight versus placebo in facilitating presurgical collection of blood for self-donation…
- Conditions
- Anemia, Blood Transfusions, Autologous, Orthopedic Procedures
- Trial name
- NCT00270140
- Testing
- epoetin alfa
- Volunteers
- 17 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Safety Issues, Effect of Drugs
Clinical Effect and Safety of Autologous Umbilical Cord Blood Transfusion in the Treatment of Cerebral Palsy
To study the clinical efficacy and safety of autologous umbilical cord blood transfusion in the treatment of cerebral palsy.
- Trial name
- NCT03791372
- Testing
- 0.9% Sodium Chloride, Autologous Umbilical Cord Blood
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Guangdong Women and Children Hospital
Cerebral Palsy
Safety and Effectiveness of Cord Blood Stem Cell Infusion for the Treatment of Cerebral Palsy in Children
The purpose of this study is to test the safety and effectiveness of a cord blood infusion in children who have motor disability due to cerebral palsy (CP).
- Trial name
- NCT01072370
- Testing
- Cord Blood Infusion
- Where
- United States
- Sponsor
- Augusta University
Type 1 Diabetes, Children
Cord Blood Infusion for Type 1 Diabetes Mellitus (T1DM)
Type 1 diabetes (T1D) is still associated with tremendous morbidity and premature mortality. Patients require multiple daily insulin injections throughout their lives as well as close monitoring of their diet and blood sugar…
- Trial name
- NCT00989547
- Testing
- Umbilical Cord Blood VITA 34
- Where
- Germany
- Volunteers
- 18 people
- Sponsor
- Technical University of Munich
Transfusion Dependent Beta-Thalassaemia
A Safety and Efficacy Study Evaluating ET-01 in Subjects with Transfusion Dependent Β-Thalassaemia
This is a single-arm, open label, multi-center, single-dose phase 1 study in subjects with transfusion dependent β-thalassaemia.
- Trial name
- ET-01 (NCT04925206)
- Testing
- ET-01
- Where
- 4 sites in China
- Volunteers
- 8 people
- Sponsor
- EdiGene (GuangZhou) Inc.